ZA964434B - Neutralizing high affinity human monoclonal antibodies specific to rsv f-protein and methods for their manufacture and therapeutic use thereof - Google Patents

Neutralizing high affinity human monoclonal antibodies specific to rsv f-protein and methods for their manufacture and therapeutic use thereof

Info

Publication number
ZA964434B
ZA964434B ZA964434A ZA964434A ZA964434B ZA 964434 B ZA964434 B ZA 964434B ZA 964434 A ZA964434 A ZA 964434A ZA 964434 A ZA964434 A ZA 964434A ZA 964434 B ZA964434 B ZA 964434B
Authority
ZA
South Africa
Prior art keywords
rsv
protein
manufacture
methods
monoclonal antibodies
Prior art date
Application number
ZA964434A
Other languages
English (en)
Inventor
Petr Brams
Soulaima Salim Chamat
Li-Zhen Pan
Edward E Walsh
Cheryl Janne Heard
Roland Anthony Newman
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of ZA964434B publication Critical patent/ZA964434B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ZA964434A 1995-06-07 1996-05-30 Neutralizing high affinity human monoclonal antibodies specific to rsv f-protein and methods for their manufacture and therapeutic use thereof ZA964434B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/488,376 US5811524A (en) 1995-06-07 1995-06-07 Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof

Publications (1)

Publication Number Publication Date
ZA964434B true ZA964434B (en) 1996-12-10

Family

ID=23939500

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA964434A ZA964434B (en) 1995-06-07 1996-05-30 Neutralizing high affinity human monoclonal antibodies specific to rsv f-protein and methods for their manufacture and therapeutic use thereof

Country Status (23)

Country Link
US (11) US5811524A (fr)
EP (2) EP2095827A1 (fr)
JP (1) JP3771267B2 (fr)
KR (1) KR100490687B1 (fr)
CN (2) CN1680447A (fr)
AR (1) AR003423A1 (fr)
AT (1) ATE431159T1 (fr)
AU (1) AU717061B2 (fr)
BR (1) BR9608884A (fr)
CA (1) CA2223033A1 (fr)
CO (1) CO4480110A1 (fr)
DE (1) DE69637930D1 (fr)
HK (1) HK1015282A1 (fr)
IL (1) IL122404A0 (fr)
MX (2) MXPA01011457A (fr)
MY (1) MY137299A (fr)
NO (1) NO324047B1 (fr)
NZ (2) NZ310847A (fr)
RS (1) RS50157B (fr)
SA (1) SA96170384B1 (fr)
UY (1) UY24255A1 (fr)
WO (1) WO1996040252A1 (fr)
ZA (1) ZA964434B (fr)

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
FR2758331B1 (fr) * 1997-01-14 1999-03-05 Univ Bourgogne Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
AU9374198A (en) * 1997-09-08 1999-03-29 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
DE69942021D1 (de) * 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
US6900299B1 (en) * 1999-03-11 2005-05-31 University Of South Florida Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection
CO5280147A1 (es) * 1999-05-18 2003-05-30 Smithkline Beecham Corp Anticuerpo humano monoclonal
GB9918788D0 (en) * 1999-08-10 1999-10-13 Leuven K U Res & Dev Antithrombotic effect of platelet glycoprotein 1b blocking monoclonal Fab fragments
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
ATE474854T1 (de) * 2000-01-27 2010-08-15 Medimmune Llc Rsv neutralisierende antikörper mit sehr hohen affinität
DE60136334D1 (en) 2000-02-02 2008-12-11 Us Health Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
CA2401652A1 (fr) * 2000-03-01 2001-09-07 Medimmune, Inc. Anticorps de recombinaison hautement efficaces et procede de production de ceux-ci
JP2003531866A (ja) * 2000-05-03 2003-10-28 メディミューン，インコーポレイテッド 抗体を用いた呼吸器疾患の組合せ治療法
JP4434580B2 (ja) * 2000-11-28 2010-03-17 メディミューン，エルエルシー 予防及び治療のために抗ｒｓｖ抗体を投与／処方する方法
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
CA2444661A1 (fr) 2001-01-31 2002-08-08 Idec Pharmaceutical Corporation Utilisation d'antagonistes cd23 dans le traitement des troubles neoplasiques
EP1412482A2 (fr) * 2001-03-23 2004-04-28 Genentech, Inc. Utilisations de ligands d'osteoprotegerine (opg) pour la modulation de reponses immunitaires
WO2002079255A1 (fr) * 2001-04-02 2002-10-10 Idec Pharmaceuticals Corporation Anticorps recombinants co-exprimes avec gntiii
WO2002102303A2 (fr) * 2001-05-01 2002-12-27 Medimmune, Inc. Cristaux et structure de synagis fab
CN1526011A (zh) * 2001-07-10 2004-09-01 IDECҩ�﹫˾ 抑制凋亡过程及改善细胞性能
CA2838062C (fr) 2001-08-03 2015-12-22 Roche Glycart Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
US7306919B1 (en) * 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
AU2002365925A1 (en) * 2001-11-02 2003-09-02 Centocor Rsv proteins, antibodies, compositions, methods and uses
JP2005538689A (ja) * 2002-02-11 2005-12-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド ワクシニアまたは天然痘に対する治療のためのヒト抗体
EP1474682A4 (fr) * 2002-02-11 2005-10-12 Alexion Pharma Inc Production d'anticorps humains chez des hotes mammiferes non humains immunodeficients
CA2480419A1 (fr) * 2002-03-28 2003-10-09 Yamanouchi Pharmaceutical Co., Ltd. Facteur de croissance associe a une antiopoietine
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
AU2003243443B2 (en) * 2002-06-21 2008-11-06 Centocor, Inc. Method for generating monoclonal antibodies
WO2004010935A2 (fr) * 2002-07-25 2004-02-05 Medimmune, Inc. Methodes de traitement et de prevention de rsv, hmpv, et piv a l'aide d'anticorps anti-rsv, anti-mpvh, et anti-piv
KR100604038B1 (ko) * 2002-08-02 2006-07-24 주식회사유한양행 항체 중쇄 발현벡터
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
CA2514062A1 (fr) * 2003-01-27 2004-08-12 Biogen Idec Ma Inc. Compositions et methodes permettant de traiter le cancer au moyen de igsf9 et de liv-1
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
HUE025347T2 (en) 2003-03-19 2016-02-29 Biogen Ma Inc NOGO receptor binding protein
US20060257972A1 (en) * 2003-03-31 2006-11-16 Takashi Ishihara Purification of human monoclonal antibody and human polyclonal antibody
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7070786B2 (en) * 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
KR20160003332A (ko) 2003-06-27 2016-01-08 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
US20050239700A1 (en) * 2003-10-14 2005-10-27 Biogen Idec Inc. Treatment of cancer using antibodies to LRRC15
WO2005047327A2 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
WO2005081749A2 (fr) * 2004-01-23 2005-09-09 Avanir Pharmaceuticals, Inc. Anticorps humains neutralisants diriges contre la toxine du charbon
WO2005056052A1 (fr) 2003-11-14 2005-06-23 Avanir Pharmaceuticals Neutralisation d'anticorps humains par rapport a une toxine d'anthrax generes par une technologie de concordance
US20060246079A1 (en) * 2003-11-14 2006-11-02 Morrow Phillip R Neutralizing human antibodies to anthrax toxin
US7750123B2 (en) * 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
EP2418224A3 (fr) 2004-03-19 2013-07-24 Amgen Inc. Réduction du risque d'anticorps humains et anti-humains par manipulation du gène V
ES2395094T3 (es) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Tratamiento de afecciones que implican la desmielinización
JP5060293B2 (ja) 2004-08-03 2012-10-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド 神経機能におけるｔａｊ
US20060063187A1 (en) * 2004-09-15 2006-03-23 Hotamisligil Gokhan S Modulation of XBP-1 activity for treatment of metabolic disorders
WO2006041970A2 (fr) * 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Infection a virus respiratoire syncytial (rsv)
US20060115485A1 (en) * 2004-10-29 2006-06-01 Medimmune, Inc. Methods of preventing and treating RSV infections and related conditions
EP2311880A3 (fr) 2005-01-05 2011-07-27 Biogen Idec MA Inc. Molécules à crypto-liaison
US7812135B2 (en) 2005-03-25 2010-10-12 Tolerrx, Inc. GITR-binding antibodies
EP2937360A1 (fr) * 2005-06-17 2015-10-28 Merck Sharp & Dohme Corp. Molécules se liant à l'ilt3 et leurs utilisations
PT1904104E (pt) 2005-07-08 2013-11-21 Biogen Idec Inc Anticorpos sp35 e suas utilizações
US20100304358A1 (en) * 2005-08-15 2010-12-02 Shuming Nie Methods of identifying biological targets and instrumentation to identify biological targets
MX2008005764A (es) 2005-11-04 2008-11-18 Biogen Idec Inc Metodos para promover el crecimiento de neuritas y la supervivencia en neuronas dopaminergicas.
JP2009516513A (ja) * 2005-11-21 2009-04-23 ラボラトワール セローノ ソシエテ アノニム ハイブリッド抗原結合分子の組成物及び製造方法並びにその使用
NZ569428A (en) 2005-12-02 2012-11-30 Biogen Idec Inc Treatment of conditions involving demyelination with a Sp35 antagonist
US9127251B2 (en) * 2005-12-09 2015-09-08 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of antibody producing cells
WO2007068758A1 (fr) * 2005-12-16 2007-06-21 Ribovax Biotechnologies Sa Procédés permettant d'obtenir des cellules sécrétant des anticorps immortalisés
DK1981902T3 (en) 2006-01-27 2015-10-05 Biogen Ma Inc Nogo Receptor Antagonists
EP2004686A1 (fr) * 2006-03-06 2008-12-24 Symphogen A/S Anticorps polyclonal de recombinaison pour le traitement d'infections par le virus respiratoire syncytial
TW200813086A (en) 2006-05-11 2008-03-16 Hoffmann La Roche Immunereconstituted mouse
WO2008094176A2 (fr) * 2006-06-19 2008-08-07 Tolerx, Inc. Molécules se liant à l'ilt3 et leurs utilisations
WO2008079322A1 (fr) * 2006-12-22 2008-07-03 Beckman Coulter, Inc. Procédés, coffrets et matériels pour diagnostiquer des états de maladie par la mesure d'isoformes ou de proformes de la myéloperoxydase
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
SI2068887T1 (sl) 2007-01-09 2014-06-30 Biogen Idec Ma Inc. SP35 protitelesa in njihova uporaba
CA2678628A1 (fr) * 2007-03-06 2008-09-12 Symphogen A/S Anticorps recombinants pour le traitement des infections au virus respiratoire syncytial
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
EP1997830A1 (fr) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. Molécules à liaison spécifiques RSV et leur moyen de fabrication
CA2693677C (fr) * 2007-07-12 2018-02-13 Tolerx, Inc. Therapies combinees utilisant des molecules de liaison au gitr
EP2201040A1 (fr) * 2007-09-24 2010-06-30 Vanderbilt University Anticorps monoclonaux au virus respiratoire syncytial et leurs utilisations
EP2217625B1 (fr) 2007-11-08 2021-08-04 Precision Biologics, Inc. Anticorps monoclonaux recombinants et antigènes correspondants pour des cancers du côlon et du pancréas
EP3192808A1 (fr) * 2007-11-27 2017-07-19 The University Of British Columbia Compositions et procédés pour la prévention et le traitement de l'arthrite
KR100938998B1 (ko) * 2008-01-08 2010-01-28 (주) 에이프로젠 호흡기 신시티움 바이러스에 대한 항체
US20090233295A1 (en) * 2008-01-29 2009-09-17 Elias Georges Trim59 directed diagnostics for neoplastic disease
WO2009147248A2 (fr) 2008-06-05 2009-12-10 Ablynx N.V. Séquences d'acides aminés dirigées contre des protéines d'enveloppe d'un virus, et polypeptides comprenant ces séquences destinés au traitement de maladies virales
EP2315779A2 (fr) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprenant des anticorps anti-lingo ou leurs fragments
EP2145621A1 (fr) 2008-07-16 2010-01-20 Stephan Lück Prévention de la déshydratation et réduction de pertes glucoformatrices d'acides aminés à l'aide de propane-1,2,3-triol
JP5575377B2 (ja) * 2008-07-18 2014-08-20 シスメックス株式会社 抗ｒｓウイルスモノクローナル抗体を用いたｒｓウイルス検出用キット及びイムノクロマトグラフィー用試験具、並びに新規な抗ｒｓウイルスモノクローナル抗体
WO2010068722A1 (fr) 2008-12-12 2010-06-17 Medimmune, Llc Cristaux et structure d'un variant de fc d'igg humain avec liaison augmentée à fcrn
CN102341411A (zh) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 抗-淋巴细胞毒素抗体
WO2010111180A1 (fr) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Anticorps humanisés dirigés contre le polypeptide light et leurs utilisations
WO2010139808A2 (fr) 2009-06-05 2010-12-09 Ablynx Nv Séquences d'acides aminés améliorées dirigées contre le virus respiratoire syncytial (rsv) humain et polypeptides les comprenant pour la prévention et/ou le traitement des infections de l'appareil respiratoire
BR112012001666A2 (pt) 2009-07-15 2019-09-24 Novartis Ag composições de proteína rsv f e métodos para fazer as mesmas
MX2012001882A (es) 2009-08-13 2012-04-11 Crucell Holland Bv Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
AU2010296058A1 (en) * 2009-09-16 2012-05-03 Duke University HIV-1 antibodies
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
SI2400298T1 (sl) * 2010-05-28 2013-11-29 F. Hoffmann-La Roche Ag Postopek kultivacije posamezne B-celice in izdelava specifičnih protiteles
CA2804280A1 (fr) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Facteurs de coagulation chimeriques
CN103097412B (zh) 2010-07-09 2016-08-10 克鲁塞尔荷兰公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
EP2422618A1 (fr) 2010-08-27 2012-02-29 Technologie Integrale Ltd. Modèle animal pour l'évaluation de l'efficacité d'un vaccin contre le VIH
WO2012109238A2 (fr) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Procédés d'augmentation des réponses immunitaires à l'aide d'agents qui se lient directement à ire-1 et activent ire-1
EP3699286A1 (fr) 2011-04-20 2020-08-26 The Trustees of the University of Pennsylvania Régimes et compositions pour l'immunisation passive médiée par aav contre des agents pathogènes en suspension dans l'air
AU2012267484B2 (en) 2011-06-10 2017-03-23 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
EP2568289A3 (fr) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunosélection du virus de la stomatite vésiculaire recombinant exprimant les protéines du VIH-1 par des anticorps largement neutralisants
EP2756092A4 (fr) * 2011-09-16 2015-10-28 Giovanni Amabile Procédés de fabrication de cellules, de tissus et d'anticorps
CN102850454B (zh) * 2011-09-27 2014-06-25 上海博沃生物科技有限公司 抗呼吸道合胞病毒的人单克隆抗体
EP2586461A1 (fr) 2011-10-27 2013-05-01 Christopher L. Parks Particules virales dérivées d'un virus enveloppé
CA2855746A1 (fr) 2011-11-16 2013-05-23 John Stephen HILL Procede de traitement de troubles associes au mutant de deletion viii du recepteur du facteur de croissance epidermique
PT2802606T (pt) 2012-01-10 2018-07-13 Biogen Ma Inc Melhoramento do transporte de moléculas terapêuticas através da barreira hematoencefálica
CA2873623C (fr) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Antagonistes de lingo-2 pour le traitement d'affections impliquant des neurones moteurs
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
JPWO2014003137A1 (ja) * 2012-06-27 2016-06-02 旭化成メディカル株式会社 高アフィニティー抗体、及びその製造方法
CA2889266A1 (fr) * 2012-11-13 2014-05-22 Genentech, Inc. Enrichissement de plasmoblastes specifiques d'antigenes
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
WO2014114801A1 (fr) 2013-01-25 2014-07-31 Amgen Inc. Anticorps ciblant cdh19 pour un mélanome
WO2014117990A1 (fr) 2013-01-29 2014-08-07 Basf Plant Science Company Gmbh Plantes résistantes aux champignons exprimant hcp6
CN104955324A (zh) 2013-01-29 2015-09-30 巴斯夫植物科学有限公司 表达hcp7的抗真菌植物
CN104981149B (zh) 2013-01-29 2022-03-04 巴斯夫植物科学有限公司 表达ein2的抗真菌植物
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
EP2970446A1 (fr) 2013-03-15 2016-01-20 Amgen Research (Munich) GmbH Constructions d'anticorps pour m2 et cd3 de grippe
SI2970449T1 (sl) 2013-03-15 2019-11-29 Amgen Res Munich Gmbh Enoverižne vezavne molekule, ki vsebujejo N-terminalni ABP
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
EP2975052B1 (fr) * 2013-03-15 2020-09-23 Xiamen University Épitope de protéine de fusion de rsv et anticorps identifiant celui-ci
WO2014203988A1 (fr) * 2013-06-21 2014-12-24 アルフレッサファーマ株式会社 Dispositif d'immunochromatographie pour détecter le vrs
EP2848937A1 (fr) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Procédés d'identification de nouveaux immunogènes du VIH-1
WO2015048331A1 (fr) 2013-09-25 2015-04-02 Cornell University Composés pour induire une immunité anti-tumorale et procédés associés
EP2873423B1 (fr) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Trimères de glycoprotéines d'enveloppe du vih -1 soluble
EP3062884B1 (fr) 2013-10-29 2020-12-02 President and Fellows of Harvard College Compositions pour l'utilisation dans le traitement de la rétinite pigmentaire
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
MX365658B (es) 2014-05-13 2019-06-10 Univ Pennsylvania Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos.
MX2017001403A (es) 2014-07-31 2017-07-07 Amgen Res (Munich) Gmbh Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
CA2956471A1 (fr) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Constructions optimisees d'anticorps monocatenaires, bispecifiques, specifiques d'especes croisees
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh Constructos de anticuerpos para cdh19 y cd3
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
CN107429259A (zh) 2015-02-04 2017-12-01 巴斯夫植物科学有限公司 通过增加莨菪亭含量，增加转基因植物中大豆锈病抗性的方法
EP3069730A3 (fr) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
TWI772258B (zh) 2015-04-17 2022-08-01 德商安美基研究（慕尼黑）公司 Ｃｄｈ３與ｃｄ３之雙特異性抗體構築體
AU2016275909A1 (en) 2015-05-13 2017-11-09 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CR20180420A (es) 2016-02-03 2018-12-05 Amgen Inc Constructos de anticuerpo biespecíficos para bcma y cd3 que se ligan a células t
DK3411404T3 (da) 2016-02-03 2023-01-30 Amgen Res Munich Gmbh Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner
US10626126B2 (en) * 2016-04-08 2020-04-21 Pulmocide Limited Compounds
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
EP3054014A3 (fr) 2016-05-10 2016-11-23 BASF Plant Science Company GmbH Utilisation d'un fongicide sur des plantes transgéniques.
BR112019008063A2 (pt) 2016-10-21 2019-07-02 Adimab Llc anticorpos contra o vírus sincicial anti-respiratório e métodos de sua geração e uso
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US11485775B2 (en) 2016-10-21 2022-11-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
CA3052487A1 (fr) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Vaccins contre la grippe bases sur des vecteurs aav
US11827906B2 (en) 2017-02-28 2023-11-28 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clade f vector and uses therefor
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
CN110913904A (zh) 2017-05-05 2020-03-24 美国安进公司 用于改善的储存和施用的包含双特异性抗体构建体的药物组合物
EP3717632B1 (fr) 2017-11-30 2022-10-26 F. Hoffmann-La Roche AG Procédé de culture de lymphocyte b
EP3724229A1 (fr) 2017-12-11 2020-10-21 Amgen Inc. Procédé de fabrication continue pour des produits d'anticorps bispécifiques
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
AU2019313444A1 (en) 2018-07-30 2021-02-18 Amgen Inc. Prolonged administration of a bispecific antibody construct binding to CD33 and CD3
CN112512581A (zh) 2018-08-03 2021-03-16 安进研发（慕尼黑）股份有限公司 针对cldn18.2和cd3的抗体构建体
AU2019327155A1 (en) 2018-08-27 2021-03-18 Affimed Gmbh Cryopreserved NK cells preloaded with an antibody construct
CN112789058A (zh) 2018-10-11 2021-05-11 安进公司 双特异性抗体构建体的下游加工
EP3938504A1 (fr) 2019-03-11 2022-01-19 Basf Se Amylases et leurs procédés de fabrication et d'utilisation
CA3137494A1 (fr) 2019-06-13 2020-12-17 Amgen Inc. Commande de perfusion contenant de la biomasse automatisee dans la fabrication de produits biologiques
AU2020345787A1 (en) 2019-09-10 2022-03-24 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity
AU2020381536A1 (en) 2019-11-13 2022-04-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
MX2022007688A (es) 2019-12-20 2022-07-19 Amgen Inc Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
AU2020414409A1 (en) 2019-12-27 2022-06-16 Affimed Gmbh Method for the production of bispecific FcyRIIl x CD30 antibody construct
WO2021150824A1 (fr) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinaisons de constructions d'anticorps et d'inhibiteurs du syndrome de libération de cytokine et leurs utilisations
US20230146593A1 (en) 2020-03-12 2023-05-11 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitor
WO2021188851A1 (fr) 2020-03-19 2021-09-23 Amgen Inc. Anticorps contre la mucine 17 et leurs utilisations
WO2021202463A1 (fr) 2020-03-30 2021-10-07 Danisco Us Inc Anticorps anti-rsv
EP4153633A1 (fr) 2020-05-19 2023-03-29 Amgen Inc. Constructions de liaison à mageb2
JP2023527972A (ja) 2020-05-29 2023-07-03 アムジエン・インコーポレーテツド Ｃｄ３３及びｃｄ３に結合する二重特異性コンストラクトの有害作用軽減投与
WO2022074206A1 (fr) 2020-10-08 2022-04-14 Affimed Gmbh Lieurs trispécifiques
AR124017A1 (es) 2020-11-06 2023-02-01 Amgen Res Munich Gmbh Polipéptidos con perfil de recorte potenciado
TW202233680A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 具有增加的選擇性之多靶向性雙特異性抗原結合分子
TW202233679A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 選擇性地與cldn6和cd3結合的多肽構建體
KR20230104229A (ko) 2020-11-06 2023-07-07 암젠 인크 Cd3에 결합하는 폴리펩티드 구축물
TW202237850A (zh) 2020-12-01 2022-10-01 賓州大學委員會 具有組織特異性靶向基序的新穎構成物及含有其之組成物
AU2022246675A1 (en) 2021-04-02 2023-10-19 Amgen Inc. Mageb2 binding constructs
CA3216585A1 (fr) 2021-04-27 2022-11-03 Nathaniel SILVER Vecteurs d'adn non viraux exprimant des anticorps therapeutiques et leurs utilisations
JP2024518369A (ja) 2021-05-06 2024-05-01 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング 増殖性疾患で使用されるｃｄ２０及びｃｄ２２標的化抗原結合分子
WO2023007023A1 (fr) 2021-07-30 2023-02-02 Affimed Gmbh Corps duplex
AR127568A1 (es) 2021-11-03 2024-02-07 Affimed Gmbh Ligandos biespecíficos de cd16a
CA3237018A1 (fr) 2021-11-03 2023-05-11 Joachim Koch Liants de cd16a bispecifiques
WO2023177655A1 (fr) 2022-03-14 2023-09-21 Generation Bio Co. Compositions vaccinales prime-boost hétérologues et méthodes d'utilisation
WO2023218027A1 (fr) 2022-05-12 2023-11-16 Amgen Research (Munich) Gmbh Molécules bispécifiques multicibles à chaînes multiples de liaison à un antigène à sélectivité accrue
WO2024059675A2 (fr) 2022-09-14 2024-03-21 Amgen Inc. Composition de stabilisation de molécule bispécifique

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0043272B1 (fr) * 1980-07-01 1984-06-13 National Research Development Corporation Production d'antigènes viraux
JPS58500366A (ja) * 1981-03-06 1983-03-10 セルテツク　リミテツド 単一クロ−ン抗体
US5340926A (en) * 1983-03-25 1994-08-23 Celltech, Limited Process for the recovery of recombinantly produced protein from insoluble aggregate
US5332805A (en) * 1984-02-03 1994-07-26 Celltech Limited Process for the recovery of recombinantly produced chymosin from insoluble aggregate
FR2590674B1 (fr) * 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
US5149650A (en) * 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4717766A (en) * 1986-01-27 1988-01-05 Miles Laboratories, Inc. Method of preparing high titer anti-respiratory syncytial virus intravenous immune globulin
US4659563A (en) * 1986-01-27 1987-04-21 Miles Laboratories, Inc. High titer anti-respiratory syncytial virus intravenous immune globulin
US5271927A (en) * 1986-02-13 1993-12-21 Celltech Limited Antibody conjugates with macrocyclic ligands
US5468606A (en) * 1989-09-18 1995-11-21 Biostar, Inc. Devices for detection of an analyte based upon light interference
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
GB8719041D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
JP2716503B2 (ja) * 1987-12-23 1998-02-18 ジ・アップジョン・カンパニー ヒト呼吸系シンシチウムウイルスの糖蛋白類の免疫原性セグメントを含有するキメラ糖蛋白類
US5183657A (en) * 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
US5137804A (en) * 1988-05-10 1992-08-11 E. I. Du Pont De Nemours And Company Assay device and immunoassay
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5354554A (en) * 1989-02-10 1994-10-11 Celltech Limited Crosslinked antibodies and processes for their preparation
US6093872A (en) * 1989-05-05 2000-07-25 Systemix, Inc. Extended human hematopoiesis in a heterologous host
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5518725A (en) * 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5279935A (en) * 1990-03-01 1994-01-18 Becton, Dickinson And Company Method of immunossay including deactivation of endogenous alkaline phosphatase
WO1991016910A1 (fr) * 1990-05-03 1991-11-14 Systemix, Inc. Tissu lymphoide humain utilise chez un hote presentant un deficit immunitaire
EP0581882B1 (fr) * 1991-04-22 1998-01-07 Massachusetts Health Research Institute, Inc. (Mhri) Procede de criblage d'echantillons de plasma pour depister des titres d'anticorps efficaces contre les virus respiratoires
AU666852B2 (en) * 1991-05-01 1996-02-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
CA2044940A1 (fr) * 1991-06-10 1992-12-11 Inder M. Verma Proto-oncogene negatif transdominant
WO1993005796A1 (fr) * 1991-09-19 1993-04-01 The Scripps Research Institute Procede de production d'anticorps humains dans un animal non humain, et animaux utilises a cet effet
US5240694A (en) * 1991-09-23 1993-08-31 University Of Virginia Combined antiviral and antimediator treatment of common colds
US5418136A (en) * 1991-10-01 1995-05-23 Biostar, Inc. Devices for detection of an analyte based upon light interference
JPH07507923A (ja) * 1992-03-20 1995-09-07 イムネット ヒトモノクローナル抗体およびヒトモノクローナル抗体製造法
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
ES2191016T3 (es) * 1992-09-16 2003-09-01 Scripps Research Inst Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial.
WO1994015640A1 (fr) * 1993-01-12 1994-07-21 Anthony George Gristina Procedes et compositions pour application directe a forte concentration d'anticorps, produisant une immunite passive
US5424189A (en) * 1993-03-05 1995-06-13 Kansas State University Research Foundation Bovine respiratory syncytial virus detection and primers
AU689489B2 (en) * 1993-07-30 1998-04-02 Oravax, Inc Monoclonal IgA antibody against respiratory syncytial virus
US5538952A (en) * 1994-05-26 1996-07-23 Abbott Laboratories Inhibition of infection of mammalian cells by respiratory syncytial virus
US5506209A (en) * 1994-05-26 1996-04-09 Abbott Laboratories Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof

Also Published As

Publication number Publication date
EP0854730A1 (fr) 1998-07-29
MX9709778A (es) 1998-07-31
CO4480110A1 (es) 1997-07-09
CN1192695A (zh) 1998-09-09
AU717061B2 (en) 2000-03-16
RS50157B (sr) 2009-05-06
KR100490687B1 (ko) 2005-08-05
CA2223033A1 (fr) 1996-12-19
CN1680447A (zh) 2005-10-12
AU6172096A (en) 1996-12-30
NZ310847A (en) 1999-05-28
EP0854730B1 (fr) 2009-05-13
US6537809B2 (en) 2003-03-25
EP0854730A4 (fr) 2002-11-06
WO1996040252A1 (fr) 1996-12-19
MXPA01011457A (es) 2005-09-08
NO975621D0 (no) 1997-12-04
EP2095827A1 (fr) 2009-09-02
US5955364A (en) 1999-09-21
DE69637930D1 (de) 2009-06-25
NO324047B1 (no) 2007-08-06
US5958765A (en) 1999-09-28
UY24255A1 (es) 1996-06-18
SA96170384B1 (ar) 2006-07-31
US6413771B1 (en) 2002-07-02
US5840298A (en) 1998-11-24
AR003423A1 (es) 1998-08-05
IL122404A0 (en) 1998-06-15
US20040076631A1 (en) 2004-04-22
NO975621L (no) 1998-02-04
CN1198648C (zh) 2005-04-27
ATE431159T1 (de) 2009-05-15
BR9608884A (pt) 1999-07-06
US5939068A (en) 1999-08-17
NZ335241A (en) 1999-07-29
JPH11507640A (ja) 1999-07-06
US5866125A (en) 1999-02-02
MY137299A (en) 2009-01-30
US20040005323A1 (en) 2004-01-08
KR19990022645A (ko) 1999-03-25
HK1015282A1 (en) 1999-10-15
JP3771267B2 (ja) 2006-04-26
US20020081723A1 (en) 2002-06-27
US20020001798A1 (en) 2002-01-03
YU36096A (sh) 1999-06-15
US5811524A (en) 1998-09-22
US20070082002A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
ZA964434B (en) Neutralizing high affinity human monoclonal antibodies specific to rsv f-protein and methods for their manufacture and therapeutic use thereof
HUP9902327A3 (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
HUP9802401A3 (en) Monoclonal antibodies specific for different epitopes of human gp39 and methods for their use in diagnosis and therapy
IL134888A0 (en) HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING THEM AND THERAPEUTIC USE THEREOF
NO980915L (no) Rekombinante anti-CD4-antistoff egnet for human terapi
IL122370A (en) Monkey monoclonal antibodies to human B7 antigens and pharmaceutical compositions containing them
EP0777497A4 (fr) Anticorps monoclonaux humains neutralisant le virus de l'immunideficience humaine
GB2303701B (en) Method of sensing human body by the use of infrared sensing device
AU5369996A (en) Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases
AU7248594A (en) Peptides and antibodies to human c5a receptor and method of treatment
AU6155896A (en) Humanized antibodies to e-selectin
HUP9601620A3 (en) N-[(1,4-diazabicyclo[2,2,2]oct-2-yl)-methyl]-benzamide derivatives, process for producing them, and their therapeutical use
IL118069A (en) Monoclonal antibody reactive to human CETP and assay method for human CETP
EP0977590A4 (fr) Anticorps monoclonaux humains
ZA969147B (en) Application of the gax protein to the treatment of cancer
ZA967742B (en) The use of cytohesin-ph peptides for influencing the ability of integrins to adhere
AUPN115095A0 (en) Analysis of and compositions and methods for the treatment of disease
AU6100196A (en) Peptide analogs and their use as haptens to elicit catalytic antibodies
GB9517538D0 (en) Production and therapeutic combinations, of antibodies
EP0407586A4 (en) Human monoclonal antibody and process for its preparation
GB9514770D0 (en) Improvements in or relating to therapeutic antibodies
AU5852094A (en) Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
HU9500986D0 (en) Agent and preparation for external application, practically useful to cure dermatological and immunological diseases
GB9516606D0 (en) Antibodies their preparation and use
IE902008L (en) HUMAN MONOCLONAL ANTIBODIES TO HIV-IMN gp120